Cue Biopharma Secures Preclinical Milestone Payment
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, announced on April 08, 2026, that it will receive a $7.5 million preclinical milestone payment from Boehringer Ingelheim under their collaboration and license agreement. This payment follows Boehringer Ingelheim’s selection and approval of its first compound for lead optimization, with Cue Biopharma expecting to receive the funds in May 2026.
Details of the Collaboration
The collaboration involves Cue Biopharma’s technology to advance the development of a candidate molecule, specifically CUE-501, a bispecific molecule intended for autoimmune and inflammatory diseases. Under the agreement, the parties can expand research and development into various B cell targeting bispecifics for autoimmune diseases, according to GlobeNewswire PE. Cue Biopharma is also eligible for up to $337.5 million in additional research, development, and commercial milestone payments, as well as royalty payments on net sales.
Company Background and Assets
Cue Biopharma develops therapeutic biologics that selectively engage memory T cell subsets to deplete pathogenic B cells for treating autoimmune and inflammatory diseases. The company’s lead autoimmune asset, CUE-401, is designed as a bifunctional molecule combining a TGF-beta moiety with an interleukin 2 (IL-2) mutein. Lucinda Warren, interim president and chief executive officer of Cue Biopharma, stated that the company is progressing CUE-401 toward the clinic while reaching this milestone in the collaboration.
Implications for Development
The milestone achievement supports Cue Biopharma’s ongoing efforts to leverage its proprietary Immuno-STAT platform, which designs biologics to modulate disease-specific T cells without broad immune effects. As a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, Cue Biopharma is led by an experienced management team, according to GlobeNewswire PE. This payment aligns with broader trends in biopharmaceutical collaborations for innovative treatments.
